Addex Therapeutics (ADXN) Corporate Presentation summary

Company overview and strategy

• Focuses on allosteric modulators for central nervous system (CNS) disorders, leveraging a validated drug discovery platform and a differentiated pharmacological approach.

• Maintains a strong balance sheet with CHF 3.3M ($3.7M) in cash as of December 31, 2024, and a cash runway through 2026.

• Dual listed on SIX Swiss Exchange and US Nasdaq Capital Market, with 128.26M outstanding shares and no debt.

• Holds a 20% equity interest in Neurosterix, a spin-out company advancing a CNS pipeline with $65M Series A funding led by Perceptive Advisors.

• Engaged in high-value industry partnerships, notably with Indivior for substance use disorder (SUD) programs.

Pipeline highlights

• Dipraglurant (mGlu5 NAM) is Phase 2 ready for post-stroke/traumatic brain injury (TBI) recovery, targeting neuroplasticity to promote sensorimotor recovery.

• GABAB PAM for SUD, partnered with Indivior, is in IND enabling studies, with $330M in potential milestones and tiered royalties.

• GABAB PAM for chronic cough is ready to start IND enabling studies in 2025, with preclinical data showing efficacy and improved tolerability over baclofen.

• Neurosterix portfolio includes M4 PAM for schizophrenia (IND enabling studies started Q3 2024), mGlu7 NAM for mood disorders, and mGlu2 NAM for mild neurocognitive disorders.

• ADX71149 (mGlu2 PAM) is under evaluation for a new indication.

Clinical and preclinical data

• Dipraglurant demonstrated significant functional recovery in preclinical stroke models and was safe and well tolerated in Phase 1 and 2 studies for neurological diseases.

• GABAB PAM candidates for cough and SUD show robust efficacy in animal models, with no signs of tolerance or adverse effects on respiratory rate, body temperature, or growth hormone at high doses.

• Compound A, a GABAB PAM, exhibited dose-dependent antitussive effects and superior tolerability compared to baclofen and P2X3 inhibitors.